Eisai gains option to novel cancer therapy, licenses out antifungal
This article was originally published in Scrip
In a flurry of licensing activity, Eisai has acquired an option to a novel targeted cancer therapy from a Japanese bioventure and has awarded the rights to an antifungal prodrug in Japan to a small local firm.
You may also be interested in...
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.